Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

The Burden of Resistant Hypertension Across the World

(2022) Luisa Campos Caldeira Brant et al.   CURRENT HYPERTENSION REPORTS

Aprocitentan and the endothelin system in resistant hypertension

(2022) Martine Clozel   CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY

Identifying and treating resistant hypertension in PRECISION: A randomized long‐term clinical trial with aprocitentan

(2022) Parisa Danaietash et al.   Journal of Clinical Hypertension

Absorption, Distribution, Metabolism, and Excretion of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Humans

(2021) Patricia N. Sidharta et al.   CURRENT DRUG METABOLISM

Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

(2021) Kazem Rahimi et al.   LANCET

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

(2021) Bin Zhou et al.   LANCET

Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension

(2020) Pierre Verweij et al.   HYPERTENSION

Prognostic Importance of On-Treatment Clinic and Ambulatory Blood Pressures in Resistant Hypertension

(2020) Claudia R.L. Cardoso et al.   HYPERTENSION

Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects

(2019) Patricia Sidharta et al.   Drug Design Development and Therapy

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

(2019) Hiddo J L Heerspink et al.   LANCET

2018 ESC/ESH Guidelines for the management of arterial hypertension

(2018) Bryan Williams et al.   EUROPEAN HEART JOURNAL

Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients

(2018) Jean Jacques Noubiap et al.   HEART

Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association

(2018) Robert M. Carey et al.   HYPERTENSION

Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

(2018) Jeffrey D Stanaway et al.   LANCET

The double challenge of resistant hypertension and chronic kidney disease

(2015) Patrick Rossignol et al.   LANCET

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

(2015) Bryan Williams et al.   LANCET

Resistant hypertension in patients with type 2 diabetes

(2014) Anna Solini et al.   JOURNAL OF HYPERTENSION

Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data

(2014)   LANCET

Endothelin-1 and the kidney - beyond BP

(2012) Neeraj Dhaun et al.   BRITISH JOURNAL OF PHARMACOLOGY

Divergent Results Using Clinic and Ambulatory Blood Pressures

(2010) George L. Bakris et al.   HYPERTENSION

Avosentan Reduces Albumin Excretion in Diabetics with Macroalbuminuria

(2009) R. R. Wenzel et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial

(2009) Michael A Weber et al.   LANCET

Role of Endothelin-1 in Clinical Hypertension

(2008) Neeraj Dhaun et al.   HYPERTENSION